title: CORRELATION OF VISUAL ACUITY WITH FIBROTIC SCAR LOCATION IN TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION EYES.
abstract: OBJECTIVE
  To determine whether the optical coherence tomography location of a subfoveal fibrovascular scar is correlated with visual outcome in eyes successfully treated with antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
  
  
  METHODS
  Fifty-six eyes from 56 patients with a subfoveal disciform scar after antivascular endothelial growth factor treatment were included. The initial and final visual acuity, fluorescein angiography, and spectral domain optical coherence tomography scar characteristics were retrospectively reviewed.
  
  
  RESULTS
  Thirty-five of 56 eyes (62.5%) were classified as having entirely subretinal pigment epithelial (sub-RPE) scars, and 21 eyes (37.5%) had subretinal component scars. Mean initial visual acuity was similar between sub-RPE and subretinal scars (20/100 vs. 20/125, P = 0.517); mean final visual acuity was better in the sub-RPE scar group (20/60 vs. 20/200, P = 0.001). Eyes with sub-RPE scar had better preservation of the external limiting membrane, ellipsoid layer, and retinal thickness (P < 0.001, P = 0.017, P = 0.004, respectively) than subretinal component scar eyes. There was no difference between the groups in scar thickness or scar area (P = 0.707, P = 0.186, respectively).
  
  
  CONCLUSIONS
  Sub-RPE location of subfoveal scarring in eyes treated for neovascular age-related macular degeneration is associated with better preservation of outer retinal structures and better vision, when compared with a subretinal scar.
authors.affiliation: *Department of Ophthalmology, McGill University, Montreal, Quebec, Canada; and †Scientific Affairs, JSS Medical Research, Montreal, Quebec, Canada.
authors.forename: Christina L
authors.initials: CL
authors.lastname: Ryu
authors.forename: Sulaiman
authors.initials: S
authors.lastname: Al-Humaid
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Rampakakis
authors.forename: Ivan J
authors.initials: IJ
authors.lastname: Galic
authors.forename: John C
authors.initials: JC
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002921:Cicatrix / Q000473:pathology*; D005260:Female; D005355:Fibrosis; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology*; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A